Form 4: Health Catalyst COO Sells Shares Under 10b5-1 Trading Plan

Health Catalyst's Chief Operating Officer, Daniel LeSueur, sold 5,209 shares of common stock at $7.5128 per share on January 6, 2025, under a pre-arranged 10b5-1 trading plan.

Summary

• Daniel LeSueur, the Chief Operating Officer of Health Catalyst, Inc., sold 5,209 shares of the company's common stock on January 6, 2025.
• The sale was executed at a price of $7.5128 per share.
• This transaction was conducted under a pre-established Rule 10b5-1 trading plan adopted by Mr. LeSueur on March 7, 2024.
• Following the transaction, Mr. LeSueur directly owns 91,253 shares of Health Catalyst common stock.

Sentiment

Score: 5

Explanation: The document reflects a routine insider transaction under a pre-arranged plan, which is neither positive nor negative for the company's outlook. It is a neutral event.

Industry Context

This is a routine disclosure of an insider stock sale under a pre-arranged trading plan, which is a common practice for executives to manage their personal finances and avoid accusations of insider trading. It does not necessarily indicate a change in the company's outlook or performance.

Comparison to Industry Standards

• Rule 10b5-1 trading plans are a standard practice among publicly traded companies to allow insiders to sell shares without being accused of trading on non-public information.
• The sale by the COO is not unusual and is similar to transactions by executives at other comparable companies such as Cerner (now Oracle Health) and Allscripts Healthcare Solutions.

Stakeholder Impact

• The sale of shares by the COO may have a minor impact on shareholder sentiment, but it is unlikely to significantly affect the company's stock price given the pre-planned nature of the transaction.

Key Dates

Keywords

Health Catalyst, HCAT, insider trading, Form 4, 10b5-1 plan, stock sale, Daniel LeSueur, Chief Operating Officer